MyFinsight
Home
Blog
About
Contact
Total revenues
$766,208K
(2.83%↑ Y/Y)
Proceeds from issuance of
debt
$850,000K
Maturities and sales of
investments
$767,277K
(886.17%↑ Y/Y)
Net income
$105,527K
(-43.17%↓ Y/Y)
Inventory
-$44,490K
(-282.82%↓ Y/Y)
Stock-based compensation
$43,458K
(15.27%↑ Y/Y)
Depreciation and
amortization
$16,411K
(-25.64%↓ Y/Y)
Deferred income taxes
$9,220K
(-67.57%↓ Y/Y)
Other long-term
liabilities
$8,704K
(320.69%↑ Y/Y)
Other
-$4,966K
Canceled cashflow
$660,681K
Unrealized foreign
exchange losses (gains)
-$6,710K
(-166.93%↓ Y/Y)
Non-cash interest
expense
$6,086K
(822.12%↑ Y/Y)
Accounts payable and
accrued liabilities
$3,100K
(216.76%↑ Y/Y)
Other assets
-$1,484K
(-191.38%↓ Y/Y)
Net cash provided by
(used in) financing...
$813,167K
(2196.93%↑ Y/Y)
Net cash provided by
(used in) investing...
$725,528K
(2669.33%↑ Y/Y)
Net cash provided by
operating activities
$220,651K
(26.52%↑ Y/Y)
Effect of exchange rate
changes on cash
$1,410K
(199.58%↑ Y/Y)
Canceled cashflow
$36,833K
Canceled cashflow
$46,715K
Canceled cashflow
$24,539K
Cost of sales
$194,999K
(28.66%↑ Y/Y)
G&a expenses
$133,363K
(28.75%↑ Y/Y)
S&m expenses
$124,927K
(21.84%↑ Y/Y)
R&d
expenses-Research And Early...
$87,291K
(-3.51%↓ Y/Y)
R&d
expenses-Marketed Products
$55,328K
(2.52%↑ Y/Y)
R&d expenses-Later
Stage Clinical...
$36,177K
(153.15%↑ Y/Y)
Other segment
expense, net
$28,596K
(-33.58%↓ Y/Y)
Net increase in
cash, cash...
$1,760,756K
(1561.70%↑ Y/Y)
Taxes paid related to
net share...
$28,180K
(-27.33%↓ Y/Y)
Payments of debt issuance
costs
$8,653K
Purchases of investments
$25,792K
(-71.11%↓ Y/Y)
Purchases of property,
plant and equipment
$20,923K
(24.78%↑ Y/Y)
Other current assets
$11,551K
(82.57%↑ Y/Y)
Accounts receivable, net
$7,159K
(-87.57%↓ Y/Y)
Other
$5,374K
(324.15%↑ Y/Y)
Accretion of discount on
investments
$455K
(-66.59%↓ Y/Y)
Back
Back
Cash Flow
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
source: myfinsight.com